Kaiser Permanente to acquire Group Health Cooperative

Healthcare provider Kaiser Permanente has signed a definitive agreement to acquire Seattle-based Group Health Cooperative, the companies announced today. Once the deal is final, Kaiser Permanente will gain approximately 590,000 new members.

“This agreement is a natural extension of our long, successful working relationship with Group Health and it provides us with the opportunity to expand access to high-quality, affordable care and coverage,” Bernard J. Tyson, Kaiser Foundation Health Plan and Hospitals chairman and CEO, said in a statement. “Kaiser Permanente and Group Health Cooperative are a natural fit. The opportunity to unite will allow us to best serve the current and future needs of our members, customers and employees. We look forward to welcoming the people of Group Health Cooperative into the Kaiser Permanente family.”

According to both companies, there will be no immediate changes to Group Health’s coverage or care. The company will be fully integrated into Kaiser Permanente and become its eighth official region of coverage, joining Colorado, Georgia, Hawaii, Mid-Atlantic States, Northern California, Northwest (Oregon, Southern Washington), and Southern California.

"For those of you who have counted on Group Health to provide you with amazing physicians and clinical teams, and the coverage your family needs, you will continue to receive the best care and coverage available," Steve Tarnoff, MD, Group Health Physicians president, said in the same statement.

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.